Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-28

Clinical Trial Update: A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon) [Phase 2]

View source ↗

Summary

Phase II study of HY209 gel for atopic dermatitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HY209 Gel

Snippet

Sponsor: Shaperon | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED